Please assess the completion status of the following clinical trial:

Trial Title: Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced adenocarcinoma of lung, measurable disease~* Non-smoker, or former light (less than 10 pack years and stopped at least 15 years); OR~* patients with known EGFR activating mutation regardless of smoking status~* ECOG(Eastern Cooperative Oncology Group) 0-1.~Cohort B (select sites only): patients with HER2 amplified or HER2 mutation-positive NSCLC; may have had prior therapy~Exclusion Criteria:~* Active brain metastases~* Prior systemic therapy for advanced disease in Cohort A only. Cohort B can have had any number of prior lines of systemic therapy.~* known EGFR wild type NSCLC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Dacomitinib (PF-00299804) in patients with EGFR mutated NSCLC or clinical characteristics defined above to enhance for EGFR mutated NSCLC
- Cohort B (Type: EXPERIMENTAL): Dacomitinib in patients with HER2 mutated or amplified NSCLC

Based on this trial design, predict the completion outcome and termination type (if applicable).